Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results
14 févr. 2019 08h30 HE
|
Achaogen, Inc.
-- Company provides update on ZEMDRI® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH...
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
14 févr. 2019 08h30 HE
|
Achaogen, Inc.
-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a...
Achaogen Announces FDA Clearance and Launch of the Thermo Scientific QMS Plazomicin Immunoassay
10 déc. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
26 nov. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Presentations at Two Investor Healthcare Conferences in November
09 nov. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Reports Third Quarter 2018 Financial Results and Provides Corporate Update
08 nov. 2018 08h01 HE
|
Achaogen, Inc.
-- Company provides update on ZEMDRITM commercialization and launch -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Achaogen,...
Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring
05 nov. 2018 09h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 8, 2018
02 nov. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin
17 oct. 2018 08h01 HE
|
Achaogen, Inc.
-- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment options -- SOUTH SAN...
Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018
03 oct. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial agents...